GlassScriptPhysician profile
Michael D Nordquist
NPI 1558867580
$1,001.71
in general payments reported to CMS, 2019-2025
20 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $209 · 2023: $177 · 2024: $263 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $280.94 | 2021-2025 | Evenity, Prolia |
| Abbvie INC. | $145.39 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $88.01 | 2021-2025 | |
| Lilly USA, LLC | $73.27 | 2021-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $42.93 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $40.26 | 2021-2023 | |
| Sanofi Pasteur INC. | $33.34 | 2024-2025 | |
| Grifols USA, LLC | $33.23 | 2024-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $31.81 | 2023-2025 | Wegovy |
| Insulet Corporation | $31.44 | 2024-2025 | Omnipod |
| Biogen, INC. | $27.81 | 2024 | Zurzuvae |
| Ge Healthcare | $26.00 | 2025 | |
| Daiichi Sankyo INC. | $24.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.37 | 2024 | Breztri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $19.17 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $15.91 | 2021 | |
| Glaxosmithkline, LLC. | $15.34 | 2023 | Arexvy, Bexsero, Pediarix |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 | |
| Kyowa Kirin, INC. | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nordquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.